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Abstract
Background: Polymorphisms in the gene that encodes the human cellular receptor for group B
coxsackieviruses and adenoviruses (HCAR) could be responsible for differences in susceptibility to
infections with these pathogens. Moreover, adenovirus subgroup C-mediated gene therapy could
be influenced by mutations in the coding exons for the aminoterminal immunoglobulin-like 1 (Ig1)
domain, which is the essential component for adenovirus fiber knob binding.
Results: Using two primersets in the adjacent intron sequences, HCAR exons 2 and 3, which
comprise the full-length Ig1 domain, were amplified by polymerase chain reactions in 108
unselected and unrelated healthy Belgian volunteers. After nucleotide sequencing, no
polymorphisms could be demonstrated in the adenovirus-binding Ig1 exons 2 and 3 of the HCAR
gene.
Conclusions: The adenovirus-binding Ig1 domain seems to be a highly conserved region in the
Caucasian population which is a reassuring finding regarding adenovector-based gene therapy.
Background
Recombinant human subgroup C adenoviruses (serotypes
2 and 5) are envisaged as efficient vector delivery systems
in gene therapy because of their ability to transfect a wide
variety of cells [1]. Successful gene delivery requires viral
entry into the target cell via specific receptor-mediated up-
take [2]. For adenoviruses from subgroups A, C, D, E and
F, the human coxsackie-adenovirus receptor (HCAR) pro-
tein functions as the primary high-affinity binding site for
the knob domains of the adenoviral fibers, elongating
from the viral capsid structure. Subsequent interactions
between the viral penton base and cell surface α vβ 3 and
α vβ 5 integrins induce virus internalization into the target
cells [3].
The gene that encodes HCAR is located on chromosome
21q11.2 and consists of seven exons that are distributed
over an area of 54 kb [4]. After translation a 365-amino
acid (aa) integral membrane glycoprotein is produced,
with an N-terminal exoplasmic domain (218 aa), a single
hydrophobic transmembrane-spanning region (21 aa)
and a highly conserved cytoplasmic tail (107 aa) [5]. The
extracellular portion of the receptor consists of two immu-
noglobulin-like domains: the N-terminal Ig1 is related to
the immunoglobulin V fold and the more C-terminal Ig2
is related to the IgC2 fold. Structural analysis of the mech-
anism of adenovirus binding to HCAR revealed that only
the Ig1 domain (exons 2 and 3) makes contact with the
fiber knob. In contrast, molecular interactions of amino
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acid residues involved in attachment of group B coxsack-
ieviruses to HCAR may reside in the Ig2 domain (exons 4
and 5) or in an overlap region between Ig1 and Ig2 [6,7].
In contrast to thorough knowledge about the structure of
HCAR and the viral binding mechanisms, little is known
about the cellular function of this protein. A first report re-
cently described that the mouse homologue of human
CAR, that shows more than 80% similarity with the hu-
man cDNA-sequence, may function naturally as a cell ad-
hesion molecule in the developing mouse brain [8].
HCAR tissue distribution and expression levels are impor-
tant parameters influencing the efficiency of adenovirus-
based gene delivery. Different groups reported a positive
correlation between tissue HCAR levels and adenoviral in-
fectivity [1,2,9]. In vivo, the receptor seems to be expressed
preferentially in epithelial cells of multiple organs. The
highest HCAR-mRNA expression was noted in heart, pan-
creas and brain whereas placenta and skeletal muscle were
HCAR-negative [10].
Fundamental polymorphisms in the coding exons for the
viral binding Ig1 and Ig2 domains, could be responsible
for a variable susceptibility to infections with the respec-
tive pathogens and replication-deficient recombinant ad-
enovectors. HCAR exons 2 and 3, which comprise the Ig1
domain, were therefore screened for mutations in 108 un-
related healthy Belgian individuals.
Results and Discussion
HCAR exons 2 and 3 were PCR-amplified in order to
search for polymorphisms in the adenovirus-binding Ig1
domain. The exon 2 PCR generated an amplicon of 306
bp in length (exon 2 coding region: 167 bp), while a 339
bp fragment was amplified in the exon 3 PCR (exon 3 cod-
ing region: 205 bp). The resulting chromatograms were
analyzed using the SeqMan multiple sequence alignment
tool (LaserGene, DNAStar, Madison, WI). Consensus se-
quences were compared with the corresponding HCAR-
sequences in Genbank using BLAST (Basic Local Align-
ment Search Tool) [12]. All the obtained sequences
showed to be 100 % identical to the sequence in Genbank
(AF200465).
A previous report documented several key residues in the
HCAR Ig1 domain that play an important role in the for-
mation of a high-affinity adenovirus knob-HCAR com-
plex [6]. Remarkable is that the sixteen predicted
interfacial amino acids are wholly conserved among five
different species, as we could deduce from the different
CAR-sequences in Genbank (human: Y07593; mouse:
Y10320; rat: AF109644; pig:AF109646; dog: AF109645).
Mutational analysis of the Ig1 domain of HCAR demon-
strated that single or multiple substitutions of these inter-
facial Ig1 residues could eliminate adenovirus attachment
[6,7]. Polymorphisms in other regions of the HCAR-mol-
ecule might also indirectly affect adenoviral binding. Nev-
ertheless, the Ig1 domain still remains the most important
domain for adenovirus entry which has also been demon-
strated by Wang and Bergelson [13] who stated that HCAR
cytoplasmic and transmembrane domains are not essen-
tial for virus infection.
No polymorphisms could be revealed in exons 2 and 3 of
the HCAR-gene among all 108 tested Caucasian individu-
als. The Ig1 domain that makes contact with the adenovi-
rus fiber knob seems to be a highly conserved area in the
HCAR protein, reinforcing the feasibility of adenovector-
based gene therapy for a Caucasian population. Further
research on other populations might be interesting.
Materials and Methods
DNA-samples of 108 unselected and unrelated Caucasian
Flemish volunteers were collected through a non-invasive
"swish-and-spit" technique, by rinsing the oral cavity with
0.9% saline solution, after which genomic DNA was ex-
tracted using a simple alkaline lysis procedure [11]. In-
formed consent was obtained from all participants.
HCAR exons 2 and 3 (Genbank accession number
AF200465) were amplified separately using polymerase
chain reactions (PCR) with primers chosen in the adjacent
intron sequences 
(HCAR-2F: 5'-TCAATGTGCTGCTTCTGAATG-3'             and
HCAR-2R: 5'-GATAGTTGCACAGACAGCTGC-3'; 
HCAR-3F: 5'-TGTAGCAGCAGGTGTATCCAG-3'             and
HCAR-3R: 5'-CTCTTACTCAGTAACCCGTTAACAC-3')
 Figure 1). Samples were amplified in a final reaction vol-
ume of 50 µl, containing 0.1 µM forward and reverse
primers, 0.5 mM dNTP's, 2.5 mM MgCl2, and 1 U Taq
polymerase (Perkin Elmer/Roche Molecular Systems,
Brussels, Belgium), pH 8.5. Both amplification profiles in-
volved an initial denaturation at 94°C for 5 min, followed
by a three step cycle of 30 sec at 94°C, 30 sec at 56°C (exon
2) or 53°C (exon 3) and 45 sec at 72°C for 35 cycles, and
ending with a final extension of 5 min at 72°C in a Gene-
Amp PCR System 9700 thermal cycler (Perkin Elmer, Fos-
ter City, CA). PCR-products were run on a polyacrylamide
gel, stained with ethidium bromide and visualized under
UV-light. The amplification products were purified using
the QIAquick PCR Purification Kit (Qiagen, Westburg,
The Netherlands) and sequenced in forward and reverse
Figure 1
Position of the forward and reverse primers in intron 1,2 and
3 of the HCAR gene.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/1
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direction using the ABI PRISM BigDye Terminator Cycle
Sequencing Reaction Kit on a ABI PRISM 310 DNA se-
quencer (Perkin Elmer Applied Biosystems, Foster City,
CA), according to the manufacturer's instructions.
Acknowledgements
We wish to thank our colleagues of the Laboratory of Clinical & Epidemi-
ological Virology for helpful comments and discussion. This work was sup-
ported by a grant of the Fund for Scientific Research (FWO), Brussels, 
Belgium.
References
1. Li Y, Pong R-C, Bergelson JM, Hall MC, Sagalowsky AI, Tseng C-P,
Wang Z, Hsieh J-T: Loss of adenoviral receptor expression in
human bladder cancer cells: a potential impact on the effica-
cy of gene therapy. Cancer Res 1999, 59:325-330
2. Fechner H, Wang X, Wang H, Jansen A, Pauschinger M, Scherubl H,
Bergelson JM, Schultheiss H-P, Poller W: Trans-complementation
of vector replication versus Coxsackie-adenovirus-receptor
overexpression to improve transgene expression in poorly
permissive cancer cells. Gene Ther 2000, 7:1954-1968
3. Bergelson JM: Receptors mediating adenovirus attachment
and internalization. Biochem Pharmacol 1999, 57:975-979
4. Bowles KR, Gibson J, Wu J, Shaffer LG, Towbin JA, Bowles NE: Ge-
nomic organization and chromosomal localization of the hu-
man Coxsackievirus B-adenovirus receptor gene. Hum Genet
1999, 105:354-359
5. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas
A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a
common receptor for coxsackie B viruses and adenoviruses
2 and 5. Science 1997, 275:1320-1323
6. Bewley MC, Springer K, Zhang Y-B, Freimuth P, Flanagan JM: Struc-
tural analysis of the mechanism of adenovirus binding to its
human cellular receptor, CAR. Science 1999, 286:1579-1583
7. Tomko RP, Johansson CB, Totrov M, Abagyan R, Frisen J, Philipson L:
Expression of the adenovirus receptor and its interaction
with the fiber knob. Exp Cell Res 2000, 255:47-55
8. Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, Kozakai
I, Kobayashi K, Kumanishi T, Watanabe YG, Odani S, Kuwano R: The
coxsackievirus-adenovirus receptor protein as a cell adhe-
sion molecule in the developing mouse brain. Mol Brain Res
2000, 77:19-28
9. Van't Hof W, Crystal RG: Manipulation of the cytoplasmic and
transmembrane domains alters cell surface levels of the cox-
sackie-adenovirus receptor and changes the efficiency of ad-
enovirus infection. Hum Gene Ther 2001, 12:25-34
10. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M,
Schoemaker RG, Van Veghel R, Houtsmuller AB, Schultheiss H-P,
Lamers JMJ, Poller W: Expression of Coxsackie adenovirus re-
ceptor and alphav-integrin does not correlate with aden-
ovector targeting in vivo indicating anatomical vector
barriers. Gene Ther 1999, 6:1520-1535
11. Lench N, Stanier P, Williamson R: Simple non-invasive method to
obtain DNA for gene analysis. Lancet 1988, 1:1356-1358
12. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local
alignment search tool. J Mol Biol 1990, 215:403-410
13. Wang X, Bergelson JM: Coxsackievirus and adenovirus recep-
tor cytoplasmic and transmembrane domains are not essen-
tial for coxsackievirus and adenovirus infection. J. Virol. 1999,
73:2559-2562